Who went big last week in our ASX small cap winners and losers list
Link copied to
Anti-cancer drug developer Patrys jumped 400 per cent last week — the biggest small cap gain we have seen in the past month.
Patrys (ASX:PAB) shares climbed from 0.4c to 2.2c on Thursday — with almost 300 million shares trading hands — after the biotech announced its PAT-DX1 antibody had killed brain cancer cells in the lab.
The DX1 antibody was placed on brain cancer tumours cut out of seven human patients.
“This is absolutely unique,” Mr Campbell said. “This is a discovery that came out of Yale University in the United States. No one else is doing these sort of cell-penetrating antibodies.”
The results were “very, very exciting”, Mr Campbell said.
Shareholders would no doubt agree.
Patrys shares settled at 1.9c on Friday.
Explorer GWR Group (GWR:ASX) climbed from 6.4c last week as high as 11c on Thursday after announcing new tungsten finds in the Northern Territory.
The shares closed at 9c on Friday.
The price of tungsten has climbed more than 50 per cent since July, pushed along by supply cut-backs in China, where about 80 per cent of the metal comes from, according to Bloomberg.
After analysing results from five drill holes, GWR found high-grade tungsten in all five samples. Copper was also present.
“All holes have hit multiple mineralised structures,” the company said in a statement.
GWR is planning to make an initial resource estimate in November.
Natural gas developer Sacgasco (ASX:SGC) soared 61 per cent for the week after a drilling update and the release of financials.
The shares closed at 13.5c on Friday.
Sacgasco has been reporting evidence of significant gas bubbling up from drilling at its Sacramento Basin site off the coast of California.
SGC reported a $5 million loss in the half-year to June 30 and had $1.1 million in the bank.
Shares in Paradigm Biopharma soared almost 50 per cent on Monday on the back of a PR blitz heralding a breakthrough discovery for the treatment of arthritis.
The shares hit 50c on Monday before closing up 54 per cent for the week at 42c.
A published, peer-reviewed case study of an Australian woman Kaye O’Loughlin has shown the drug significantly reduced her pain and knee swelling, while improving joint function to the point she longer needs a total knee replacement.
Here are the best performing ASX small cap stocks for Sep 11-15:
Gold explorer Explaurum was sold down 31 per cent despite announcing a 125 per cent increased estimate for its Tampia Gold Project in Western Australia.
Explaurum (ASX:EXU) now expects the project to come in at 700,000 oz of gold.
Explaurum is focused on the early stage exploration of its Tampia Gold Project in Western Australia, and was “unable to comment on the likely results from the Company’s planned activities on Tampia due to the speculative nature of such activities”.
Explaurum, which had $2.4 million in the bank at the end of June, is now working towards a feasibility study for the project.
Explaurum’s shares closed at 11.5c on Friday, down from 17c at the start of the week.
Digital currency software developer DigitalX (ASX:DCC) lost 25 per cent for the week following steep drops in the value of the most popular virtual money, BitCoin.
DigitalX is developing BitCoin ATMs in a joint venture with hardware maker Stargroup (ASX:STL).
The value of BitCoin dropped 40 per cent to $US2972 ($3714) on Friday – a drop of 40 per cent from a high of $US5000 earlier this month — before recovering to $US3710.
The drop came after reports that China would ban exchange-trading of cryptocurrencies by the end of September.
Here are the worst performing ASX small cap stocks for Sep 11-15: